Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rare Diseases 1Oligodendroglioma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Brain Neoplasms 1Astrocytoma 1

Interventions

Collagenases 2Streptozocin 1Propofol 1Prednisone 1Midazolam 1Mercaptopurine 1Leuprolide 1Infliximab 1Immunoglobulins 1Fentanyl 1Carmustine 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Rare Diseases × Carmustine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡